ZIOPHARM Provides Update Regarding Phase I Study of Gene

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
ZIOPHARM Provides Update Regarding Phase I Study of Gene Therapy Candidate Ad-RTS-hIL-12 in Brain Cancer

BOSTON, July 19, 2016 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP ) today provided an update regarding the Company's ongoing multicenter Phase I study of Ad-RTS-hIL-12 + orally administered veledimex in recurrent or progressive glioblastoma (GBM) or grade III malignant glioma. 

The patient death resulting from intracranial hemorrhage in the third cohort of this Phase I study was deemed unrelated to study drug following the receipt and analysis of additional information by the sponsor and the study’s Safety Review Committee. As with all study events, the Company expects to report the data to the U.S. Food and Drug Administration in accordance with the study’s protocol and applicable regulations. As previously announced, the study remains open for enrollment. The Company expects to provide further updates on the progress of the study, including longer-term survival follow up, at an appropriate meeting later this year.

“Recurrent GBM is a devastating disease with an expected overall survival that remains far too short as this case illustrates,” said Francois Lebel, M.D., Executive Vice President, Research and Development, Chief Medical Officer at ZIOPHARM. “Preliminary overall survival in this study, including a median follow-up of over 8 months in the first dose cohort, remain encouraging, and we will continue to work diligently toward understanding the full potential of Ad-RTS-hIL-12 + veledimex in this disease, with the goal of providing safe and effective treatment options to these patients."

About Glioblastoma

Glioblastoma is an aggressive primary brain tumor affecting approximately 74,000 people worldwide each year. i, ii Recurrent glioblastoma is an aggressive cancer with one of the lowest 3-year survival rates, at 3%, among all cancers. iii For patients who have experienced multiple recurrences the prognosis is particularly poor, with a median overall survival (OS) of 6-7 months, while OS in patients that have failed temozolomide and bevacizumab, or equivalent salvage chemotherapy, is approximately 3-5 months. iv, v

About ZIOPHARM Oncology, Inc.:

ZIOPHARM Oncology is a Boston, Massachusetts-based biotechnology company employing novel gene expression, control and cell technologies to deliver safe, effective and scalable cell- and viral-based therapies for the treatment of cancer. The Company's immuno-oncology programs, in collaboration with Intrexon Corporation (NYSE: XON ) and the MD Anderson Cancer Center, include chimeric antigen receptor T cell (CAR-T) and other adoptive cell-based approaches that use non-viral gene transfer methods for broad scalability. The Company is advancing programs in multiple stages of development together with Intrexon Corporation's RheoSwitch Therapeutic System® technology, a switch to turn on and off, and precisely modulate, gene expression in order to improve therapeutic index. The Company's pipeline includes a number of cell-based therapeutics in both clinical and preclinical testing which are focused on hematologic and solid tumor malignancies.

Forward-Looking Safe-Harbor Statement:

This press release contains certain forward-looking information about ZIOPHARM Oncology, Inc. that is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as "may," "will," "could," "expects," "plans," "anticipates," and "believes." These statements include, but are not limited to, statements regarding the progress, timing and results of preclinical and clinical trials involving the Company's drug candidates, and the progress of the Company's research and development programs. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied by, the forward-looking statements. These risks and uncertainties include, but are not limited to: whether chimeric antigen receptor T cell (CAR T) approaches, Ad-RTS-hIL-12, TCR and NK cell-based therapies, or any of our other therapeutic candidates will advance further in the pre-clinical or clinical trials process and whether and when, if at all, they will receive final approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies and for which indications; whether chimeric antigen receptor T cell (CAR T) approaches, Ad-RTS-hIL-12, TCR and NK cell-based therapies, and our other therapeutic products will be successfully marketed if approved; the strength and enforceability of our intellectual property rights; competition from other pharmaceutical and biotechnology companies; and the other risk factors contained in our periodic and interim SEC reports filed from time to time with the Securities and Exchange Commission, including but not limited to, our Annual Report on Form 10-K for the fiscal year ended December 31, 2015, and our Quarterly Report for the quarter ended March 31, 2016. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and we do not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events.

Trademarks:

RheoSwitch Therapeutic System ® (RTS ® ) technology is a registered trademark of Intrexon Corporation.

i . Mrugala MM. Advances and challenges in the treatment of glioblastoma: a clinician's perspective. Discov Med. 2013;15:221-230. http://www.discoverymedicine.com/Maciej-M-Mru...rspective/. Accessed March 24, 2015. ii . McCubrey JA, LaHair MM, Franklin RA. OSU—0312 in the treatment of glioblastoma. Mol Pharmacol. 2006;70:437-439. iii . International Agency for Research on Cancer.  World Cancer Report . 2003.  http://www.iarc.fr/en/publications/pdfs-onlin...Report.pdf . iv . Omuro, A. Glioblastoma and Other Malignant Gliomas. A Clinical Review  JAMA .  2013  Nov 6;310(17):1842-50. v . Iwamoto et al. Patterns or relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology 2009; 73(15):1200-1206

Contact: Lori Ann Occhiogrosso ZIOPHARM Oncology, Inc. 617-259-1987 locchiogrosso@ziopharm.com David Pitts Argot Partners 212-600-1902 david@argotpartners.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Radiology Staffing Gap Deepens as Imaging Demand Rises

Updated Category News Views 112

An imaging order does not mean much if nobody is available to read it, and that plain operational fact sits at the center of Medicus Healthcare Solutions' 2026 report on the radiologist shortage. The report's projected gap of 2,450 full-time-equivalent radiologists in 2027 is troubling enough. Its estimate of a 4,130 FTE shortfall by 2032 is the part that should make...

Continue Reading
Shenzhen's Vertical Factories Put Robotics on Fast Track

Updated Category News Views 26

A truck climbing to a ninth-floor factory is the sort of detail that cuts through the usual innovation fog. Shenzhen's Honghualing industrial base in Nanshan is built around that odd-looking reality: keep engineers, component makers, automated lines and test customers stacked close together, then squeeze time out of the process. For anybody watching robotics, LiDAR and...

Continue Reading
Lummus-Versalis Deal Adds Nine Elastomer Technologies

Updated Category News Views 187

Nine elastomer technologies do not make a flashy headline, yet this is the sort of chemical-industry move that can matter long after the applause dies down. Lummus Technology and Versalis have expanded their partnership to cover nine elastomer technologies. That is the disclosed fact, and it is meaningful on its own. The release does not lay out contract value, duration,...

Continue Reading
Fox Hill Steel Marks a Long Public-Building Road Ahead

Updated Category News Views 70

A signed steel beam is a fine civic moment, but it is not the finish line. Burlington’s new Fox Hill Elementary School has reached its topping-off milestone, with the structural steel now in place for a 91,000-square-foot, two-story facility intended to serve roughly 325 kindergarten-through-fifth-grade students. That is tangible progress, the sort nobody can fake with...

Continue Reading
Texas Restaurants Get a New Read on Customer Demand

Updated Category News Views 195

Texas restaurant owners are being handed a sharper flashlight, and frankly it is overdue. HundredX and the Texas Restaurant Association have launched a pilot that gives TRA members access to the HundredX Restaurant Insights Platform, aiming to bring customer and market intelligence to the independent operators and regional chains that usually cannot pay big-company prices...

Continue Reading
ArchiPro Enters U.S. Design Market With Curated Bet

Updated Category News Views 56

Blue-chip furniture and glossy project photos are not a moat by themselves, no matter how hard a platform tries to make them look like one. But ArchiPro’s full U.S. launch deserves a closer look because it arrives with something many would-be marketplace operators lack: more than a decade of operating history in New Zealand and Australia. A Three-Sided Machine Meets...

Continue Reading
Another Nine's A9OS Puts Software at Center of Golf

Updated Category News Views 100

A golf simulator chain is trying to turn the boring plumbing into its sharpest club. Another Nine’s A9OS is not merely a booking widget dressed up for a franchise brochure; it is meant to run the whole 24/7 operation, from payments and door access to cameras, simulator support and guest help. That ambition deserves attention because this is exactly where a staff-free...

Continue Reading
Watson Motion Tests Military Pretrial Confinement Rules

Updated Category News Views 170

Military confinement fights are rarely neat, and this one comes with a short clock but plenty of unanswered questions. Defense lawyers for U.S. Air Force Maj. Jason Watson argued on Nov. 17 that he should be released from pretrial confinement while his case proceeds. A military judge is ordinarily expected to issue a ruling within 14 days of the hearing, under the court's...

Continue Reading
Leatt Sets Its Virtual 2026 Shareholder Meeting Date

Updated Category News Views 73

A calendar notice is not a catalyst, but ignoring the calendar is how shareholders miss the small moments that matter. Leatt Corporation has scheduled its 2026 virtual annual general meeting of stockholders for Friday, November 20, at 11:00 AM Eastern Time. For holders of OTCQB:LEAT, this is a basic corporate-governance event, not a new product launch or a financial...

Continue Reading
Esquire Spotlight Puts Trauma Cleanup Work in Focus

Updated Category News Views 96

A national magazine profile is an odd milestone for a business built around other people’s worst days. David Lesaffre, co-owner and operator of T.A.C.T. 48, T.A.C.T. AZ, and T.A.C.T. Fort Worth, has been featured by Esquire in a piece called “The Trauma Cleaners.” The attention is deserved, frankly, because biohazard remediation is one of those necessary services...

Continue Reading

Top 5 Most Recently Viewed Articles

Strategies for Investing During Market Peaks Explained

Updated Category News Views 291

Understanding Market Behaviors: Peaks and Investment Strategies The stock market has a tendency to rise over time. Historically, whether viewed through six-month, one-year, or even five-year lenses, the S&P 500 has consistently produced positive returns. This pattern holds true even as the market reaches record highs, a phenomenon that has drawn attention from analysts....

Continue Reading
Holborn Assets Launches Innovative App for Wealth Management

Updated Category News Views 212

Holborn Assets Introduces a Cutting-Edge Financial App In a significant move that underscores its commitment to digital transformation, Holborn Assets has rolled out an innovative app aimed at optimizing wealth management for its clients. This comprehensive financial management solution is specifically designed to provide users with seamless access to their financial...

Continue Reading
Growth of Mobivity's Connected Rewards in the Retail Sector

Updated Category News Views 137

Enhancing Customer Engagement with Connected Rewards Mobivity Holdings Corp. (OTCQB: MFON) has recently witnessed a remarkable surge in its Connected Rewards technology adoption among convenience store retailers. This significant development highlights how effective customer engagement solutions can reshape the retail landscape, particularly during the recent quarter. A...

Continue Reading
Coherent Boosts Silicon Carbide Production for AI and Datacenters

Updated Category News Views 192

Coherent Enhances Its Silicon Carbide Platform Coherent Corp. (NYSE: COHR), a global leader in photonics, has recently made significant strides in its development of silicon carbide (SiC) technology to meet the growing thermal efficiency needs of artificial intelligence in datacenter infrastructures. This advancement represents a major milestone for the company in its...

Continue Reading
World Bank's Commitment to Bangladesh: Over $2 Billion for Reforms

Updated Category News Views 140

World Bank Commits Over $2 Billion to Bangladesh The World Bank has recently made a major announcement regarding financial support for Bangladesh, pledging more than $2 billion for the current fiscal year. This funding is designed to help accelerate ongoing reform efforts, improve response to natural disasters, and enhance healthcare services and air quality throughout...

Continue Reading